{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T05:01:54Z","timestamp":1791435714921,"version":"4.3.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,12,9]],"date-time":"2016-12-09T00:00:00Z","timestamp":1481241600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["GA 309449"],"award-info":[{"award-number":["GA 309449"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ERA-NET Neuron","award":["MR\/M501803\/1"],"award-info":[{"award-number":["MR\/M501803\/1"]}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-IAHU-01"],"award-info":[{"award-number":["ANR-10-IAHU-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s10875-016-0359-1","type":"journal-article","created":{"date-parts":[[2016,12,8]],"date-time":"2016-12-08T23:08:00Z","timestamp":1481238480000},"page":"123-132","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":207,"title":["Assessment of Type I Interferon Signaling in Pediatric Inflammatory Disease"],"prefix":"10.1007","volume":"37","author":[{"given":"Gillian I.","family":"Rice","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Melki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Louise","family":"Fr\u00e9mond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy A.","family":"Briggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu P.","family":"Rodero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kitabayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Oojageer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Bader-Meunier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Belot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bodemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Quartier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanick J.","family":"Crow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,9]]},"reference":[{"key":"359_CR1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1749-6632.2011.06220.x","volume":"1238","author":"YJ Crow","year":"2011","unstructured":"Crow YJ. Type I, interferonopathies: a novel set of inborn errors of immunity. Ann N Y Acad Sci. 2011;1238:91\u20138.","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"359_CR2","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/nri3850","volume":"15","author":"YJ Crow","year":"2015","unstructured":"Crow YJ, Manel N. Aicardi-Goutieres syndrome and the type I interferonopathies. Nat Rev Immunol. 2015;15(7):429\u201340.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"359_CR3","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/j.cell.2016.05.057","volume":"165","author":"R Banchereau","year":"2016","unstructured":"Banchereau R, Hong S, Cantarel B, et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. Cell. 2016;165(6):1548\u201350.","journal-title":"Cell"},{"issue":"5","key":"359_CR4","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ana.20464","volume":"57","author":"SA Greenberg","year":"2005","unstructured":"Greenberg SA, Pinkus JL, Pinkus GS, et al. Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005;57(5):664\u201378.","journal-title":"Ann Neurol"},{"key":"359_CR5","doi-asserted-by":"crossref","unstructured":"Fr\u00e9mond ML, Rodero MP, Jeremiah N, et al. Efficacy of the Janus Kinase 1\/2 Inhibitor Ruxolitinib in the Treatment of Vasculopathy Associated with TMEM173-Activating Mutations in three children. J Allergy Clin Immunol. 2016.","DOI":"10.1016\/j.jaci.2016.07.015"},{"issue":"6","key":"359_CR6","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/ana.410440608","volume":"44","author":"F Goutieres","year":"1998","unstructured":"Goutieres F, Aicardi J, Barth PG, Lebon P. Aicardi-Goutieres syndrome: an update and results of interferon-alpha studies. Ann Neurol. 1998;44(6):900\u20137.","journal-title":"Ann Neurol"},{"issue":"Suppl A","key":"359_CR7","doi-asserted-by":"crossref","first-page":"A47","DOI":"10.1053\/ejpn.2002.0574","volume":"6","author":"P Lebon","year":"2002","unstructured":"Lebon P, Meritet JF, Krivine A, Rozenberg F. Interferon and Aicardi-Goutieres syndrome. Eur J Paediatr Neurol. 2002;6(Suppl A):A47\u201353. discussion A55-48, A77-86.","journal-title":"Eur J Paediatr Neurol"},{"issue":"6","key":"359_CR8","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1002\/art.21890","volume":"54","author":"J Hua","year":"2006","unstructured":"Hua J, Kirou K, Lee C, Crow MK. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum. 2006;54(6):1906\u201316.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"359_CR9","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1002\/art.24555","volume":"60","author":"TB Niewold","year":"2009","unstructured":"Niewold TB, Kariuki SN, Morgan GA, Shrestha S, Pachman LM. Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy. Arthritis Rheum. 2009;60(6):1815\u201324.","journal-title":"Arthritis Rheum"},{"issue":"3","key":"359_CR10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000235158","volume":"84","author":"YJ Seo","year":"2009","unstructured":"Seo YJ, Kim GH, Kwak HJ, et al. Validation of a HeLa Mx2\/Luc reporter cell line for the quantification of human type I interferons. Pharmacology. 2009;84(3):135\u201344.","journal-title":"Pharmacology"},{"issue":"3","key":"359_CR11","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/ar3017","volume":"12","author":"Y Li","year":"2010","unstructured":"Li Y, Lee PY, Kellner ES, et al. Monocyte surface expression of Fcgamma receptor RI (CD64), a biomarker reflecting type-I interferon levels in systemic lupus erythematosus. Arthritis Res Ther. 2010;12(3):R90.","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"359_CR12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0025858","volume":"6","author":"M Berger Rentsch","year":"2011","unstructured":"Berger Rentsch M, Zimmer G. A vesicular stomatitis virus replicon-based bioassay for the rapid and sensitive determination of multi-species type I interferon. PLoS One. 2011;6(10), e25858.","journal-title":"PLoS One"},{"issue":"6","key":"359_CR13","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1084\/jem.20021553","volume":"197","author":"L Bennett","year":"2003","unstructured":"Bennett L, Palucka AK, Arce E, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med. 2003;197(6):711\u201323.","journal-title":"J Exp Med"},{"issue":"5","key":"359_CR14","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","volume":"100","author":"EC Baechler","year":"2003","unstructured":"Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A. 2003;100(5):2610\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"359_CR15","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S1474-4422(13)70258-8","volume":"12","author":"GI Rice","year":"2013","unstructured":"Rice GI, Forte GM, Szynkiewicz M, et al. Assessment of interferon-related biomarkers in Aicardi-Goutieres syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case\u2013control study. Lancet Neurol. 2013;12(12):1159\u201369.","journal-title":"Lancet Neurol"},{"issue":"11","key":"359_CR16","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/ng.2414","volume":"44","author":"GI Rice","year":"2012","unstructured":"Rice GI, Kasher PR, Forte GM, et al. Mutations in ADAR1 cause Aicardi-Goutieres syndrome associated with a type I interferon signature. Nat Genet. 2012;44(11):1243\u20138.","journal-title":"Nat Genet"},{"issue":"1\u20132","key":"359_CR17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","volume":"13","author":"EC Baechler","year":"2007","unstructured":"Baechler EC, Bauer JW, Slattery CA, et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med. 2007;13(1\u20132):59\u201368.","journal-title":"Mol Med"},{"issue":"5","key":"359_CR18","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ng.2933","volume":"46","author":"GI Rice","year":"2014","unstructured":"Rice GI, Del Toro DY, Jenkinson EM, et al. Gain-of-function mutations in IFIH1 cause a spectrum of human disease phenotypes associated with upregulated type I interferon signaling. Nat Genet. 2014;46(5):503\u20139.","journal-title":"Nat Genet"},{"issue":"2","key":"359_CR19","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1136\/jmedgenet-2013-102038","volume":"51","author":"JH Livingston","year":"2014","unstructured":"Livingston JH, Lin JP, Dale RC, et al. A type I interferon signature identifies bilateral striatal necrosis due to mutations in ADAR1. J Med Genet. 2014;51(2):76\u201382.","journal-title":"J Med Genet"},{"issue":"8","key":"359_CR20","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/ng1845","volume":"38","author":"YJ Crow","year":"2006","unstructured":"Crow YJ, Hayward BE, Parmar R, et al. Mutations in the gene encoding the 3\u2032-5\u2032 DNA exonuclease TREX1 cause Aicardi-Goutieres syndrome at the AGS1 locus. Nat Genet. 2006;38(8):917\u201320.","journal-title":"Nat Genet"},{"issue":"8","key":"359_CR21","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/ng1842","volume":"38","author":"YJ Crow","year":"2006","unstructured":"Crow YJ, Leitch A, Hayward BE, et al. Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutieres syndrome and mimic congenital viral brain infection. Nat Genet. 2006;38(8):910\u20136.","journal-title":"Nat Genet"},{"issue":"7","key":"359_CR22","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/ng.373","volume":"41","author":"GI Rice","year":"2009","unstructured":"Rice GI, Bond J, Asipu A, et al. Mutations involved in Aicardi-Goutieres syndrome implicate SAMHD1 as regulator of the innate immune response. Nat Genet. 2009;41(7):829\u201332.","journal-title":"Nat Genet"},{"issue":"2","key":"359_CR23","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/ng.748","volume":"43","author":"TA Briggs","year":"2011","unstructured":"Briggs TA, Rice GI, Daly S, et al. Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat Genet. 2011;43(2):127\u201331.","journal-title":"Nat Genet"},{"issue":"2","key":"359_CR24","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/ng.749","volume":"43","author":"E Lausch","year":"2011","unstructured":"Lausch E, Janecke A, Bros M, et al. Genetic deficiency of tartrate-resistant acid phosphatase associated with skeletal dysplasia, cerebral calcifications and autoimmunity. Nat Genet. 2011;43(2):132\u20137.","journal-title":"Nat Genet"},{"issue":"6","key":"359_CR25","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1312625","volume":"371","author":"Y Liu","year":"2014","unstructured":"Liu Y, Jesus AA, Marrero B, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med. 2014;371(6):507\u201318.","journal-title":"N Engl J Med"},{"issue":"8","key":"359_CR26","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.4049\/jimmunol.1001731","volume":"185","author":"DM Santer","year":"2010","unstructured":"Santer DM, Hall BE, George TC, et al. C1q deficiency leads to the defective suppression of IFN-alpha in response to nucleoprotein containing immune complexes. J Immunol. 2010;185(8):4738\u201349.","journal-title":"J Immunol"},{"issue":"7532","key":"359_CR27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nature13801","volume":"517","author":"X Zhang","year":"2015","unstructured":"Zhang X, Bogunovic D, Payelle-Brogard B, et al. Human intracellular ISG15 prevents interferon-alpha\/beta over-amplification and auto-inflammation. Nature. 2015;517(7532):89\u201393.","journal-title":"Nature"},{"issue":"9","key":"359_CR28","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/ni.2948","volume":"15","author":"SC Eckard","year":"2014","unstructured":"Eckard SC, Rice GI, Fabre A, et al. The SKIV2L RNA exosome limits activation of the RIG-I-like receptors. Nat Immunol. 2014;15(9):839\u201345.","journal-title":"Nat Immunol"},{"issue":"11","key":"359_CR29","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1172\/JCI81260","volume":"125","author":"A Brehm","year":"2015","unstructured":"Brehm A, Liu Y, Sheikh A, et al. Additive loss-of-function proteasome subunit mutations in CANDLE\/PRAAS patients promote type I IFN production. J Clin Invest. 2015;125(11):4196\u2013211.","journal-title":"J Clin Invest"},{"issue":"2","key":"359_CR30","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ajhg.2014.11.019","volume":"96","author":"MA Jang","year":"2015","unstructured":"Jang MA, Kim EK, Now H, et al. Mutations in DDX58, which encodes RIG-I, cause atypical Singleton-Merten syndrome. Am J Hum Genet. 2015;96(2):266\u201374.","journal-title":"Am J Hum Genet"},{"issue":"5","key":"359_CR31","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/ni.3409","volume":"17","author":"P Starokadomskyy","year":"2016","unstructured":"Starokadomskyy P, Gemelli T, Rios JJ, et al. DNA polymerase-alpha regulates the activation of type I interferons through cytosolic RNA:DNA synthesis. Nat Immunol. 2016;17(5):495\u2013504.","journal-title":"Nat Immunol"},{"issue":"7","key":"359_CR32","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1084\/jem.20151529","volume":"213","author":"ME Meuwissen","year":"2016","unstructured":"Meuwissen ME, Schot R, Buta S, et al. Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo-TORCH syndrome. J Exp Med. 2016;213(7):1163\u201374.","journal-title":"J Exp Med"},{"issue":"12","key":"359_CR33","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1084\/jem.20161596","volume":"213","author":"MP Rodero","year":"2016","unstructured":"Rodero MP, Crow YJ. Type I interferon-mediated monogenic autoinflammation: the type I interferonopathies, a conceptual overview. J Exp Med. 2016;213(12):2527\u201338.","journal-title":"J Exp Med"},{"issue":"10","key":"359_CR34","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa1307361","volume":"370","author":"Q Zhou","year":"2014","unstructured":"Zhou Q, Yang D, Ombrello AK, et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014;370(10):911\u201320.","journal-title":"N Engl J Med"},{"issue":"10","key":"359_CR35","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1056\/NEJMoa1307362","volume":"370","author":"P Navon Elkan","year":"2014","unstructured":"Navon Elkan P, Pierce SB, Segel R, et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. N Engl J Med. 2014;370(10):921\u201331.","journal-title":"N Engl J Med"},{"issue":"7","key":"359_CR36","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/ng.398","volume":"41","author":"M Henneke","year":"2009","unstructured":"Henneke M, Diekmann S, Ohlenbusch A, et al. RNASET2-deficient cystic leukoencephalopathy resembles congenital cytomegalovirus brain infection. Nat Genet. 2009;41(7):773\u20135.","journal-title":"Nat Genet"},{"issue":"4","key":"359_CR37","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.ejpn.2016.03.009","volume":"20","author":"D Tonduti","year":"2016","unstructured":"Tonduti D, Orcesi S, Jenkinson EM, et al. Clinical, radiological and possible pathological overlap of cystic leukoencephalopathy without megalencephaly and Aicardi-Goutieres syndrome. Eur J Paediatr Neurol. 2016;20(4):604\u201310.","journal-title":"Eur J Paediatr Neurol"},{"issue":"6","key":"359_CR38","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.jaci.2015.01.040","volume":"135","author":"AL Mathieu","year":"2015","unstructured":"Mathieu AL, Verronese E, Rice GI, et al. PRKDC mutations associated with immunodeficiency, granuloma, and autoimmune regulator-dependent autoimmunity. J Allergy Clin Immunol. 2015;135(6):1578\u201388. e1575.","journal-title":"J Allergy Clin Immunol"},{"issue":"18","key":"359_CR39","doi-asserted-by":"crossref","first-page":"2867","DOI":"10.1182\/blood-2014-08-591370","volume":"124","author":"PK Chakraborty","year":"2014","unstructured":"Chakraborty PK, Schmitz-Abe K, Kennedy EK, et al. Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD). Blood. 2014;124(18):2867\u201371.","journal-title":"Blood"},{"issue":"12","key":"359_CR40","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/ng.975","volume":"43","author":"SM Al-Mayouf","year":"2011","unstructured":"Al-Mayouf SM, Sunker A, Abdwani R, et al. Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus. Nat Genet. 2011;43(12):1186\u20138.","journal-title":"Nat Genet"},{"issue":"1","key":"359_CR41","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cell.2016.05.034","volume":"166","author":"V Sisirak","year":"2016","unstructured":"Sisirak V, Sally B, D\u2019Agati V, et al. Digestion of chromatin in apoptotic cell microparticles prevents autoimmunity. Cell. 2016;166(1):88\u2013101.","journal-title":"Cell"},{"issue":"9","key":"359_CR42","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1084\/jem.20070070","volume":"204","author":"F Allantaz","year":"2007","unstructured":"Allantaz F, Chaussabel D, Stichweh D, et al. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. J Exp Med. 2007;204(9):2131\u201344.","journal-title":"J Exp Med"},{"issue":"5","key":"359_CR43","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/ard.2010.134254","volume":"70","author":"P Quartier","year":"2011","unstructured":"Quartier P, Allantaz F, Cimaz R, et al. A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis. 2011;70(5):747\u201354.","journal-title":"Ann Rheum Dis"},{"key":"359_CR44","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cyto.2015.08.045","volume":"76","author":"CD Conrad","year":"2015","unstructured":"Conrad CD, Domizio JD, Mylonas A, et al. Paradoxical psoriasis\u2014unabated type I IFN production induced by TNF blockade. Cytokine. 2015;76:66\u2013112.","journal-title":"Cytokine"},{"issue":"5","key":"359_CR45","volume":"5","author":"S Oon","year":"2016","unstructured":"Oon S, Wilson NJ, Wicks I. Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway. Clin Transl Immunol. 2016;5(5), e79.","journal-title":"Clin Transl Immunol"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-016-0359-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10875-016-0359-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-016-0359-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,16]],"date-time":"2019-09-16T06:31:28Z","timestamp":1568615488000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10875-016-0359-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,9]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["359"],"URL":"https:\/\/doi.org\/10.1007\/s10875-016-0359-1","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,9]]}}}